2012•World Clinical DrugsRequires access

Advance in the development of directly anti-HCV agents: telaprevir and boceprevir

Fen Sun

Abstract

Development of directly acting antivirals(DAAs) is important to drug therapy for chronic hepatitis C(CHC).Hepatitis C virus(HCV) NS3/4A serine protease is the vitals for the processing and maturation of viral protein precursors and RNA replication.This review focuses on the recent advances in the development of directly anti-HCV agents telaprevir and boceprevir.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Boceprevir, Telaprevir, Medicine, Virology, NS3, Hepatitis C virus, Viral replication, Virus